Lung Cancer: Page 2

Delfi tapped for European lung cancer screening study
By LabPulse.com staff writers
The trial will explore how often people should get screened for lung cancer if their initial CT exam is negative; Delfi's liquid biopsy testing will help investigators assess whether study participants could benefit from a screening CT exam. The trial is being conducted via a partnership with the Netherlands Cancer Institute (NKI) and the institute for DiagNostic Accuracy (iDNA). Delfi will work with the first 9,000 study participants enrolled in the trial through the NKI and Gustave Roussy in Villejuif, France, it said.
September 11, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
OncoCyte nabs five-year supply contract for lung cancer test
By LabPulse.com staff writers
A molecular stratification test, DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.
August 30, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Guardant expands use of liquid biopsy test to breast, lung cancer
By LabPulse.com staff writers
Guardant Reveal identifies circulating tumor DNA in blood as soon as three weeks after surgery and eliminates the need for a tissue biopsy, the company said.
August 14, 2022
2019 04 24 18 42 4242 Dna Blue 400
Gene analysis sees success in cancer treatment study
By LabPulse.com staff writers
In research presented Sunday at the International Association for the Study of Lung Cancer (IASLC) meeting in Vienna, a team led by Dr. Kei Morikawa of St. Marianna University School of Medicine in Kawasaki, Japan, has found that gene analysis using cytological specimens had a high success rate and that the yield and quality of extracted nucleic acid were adequate for panel analysis.
August 7, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Guardant Health highlights clinical results at IASLC
By LabPulse.com staff writers
A study that used Guardant's GuardantInform database analyzed information from more than 2,000 patients with any EGFR mutation who had undergone osimertinib therapy, as well as outcomes from this therapy up to five years after it began. It showed a 12.5% incidence of the mutation in lung cancer patients unlikely to respond to the treatment, the company said.
August 7, 2022
2020 06 01 18 51 2022 Cancer Lung 400
Foundation Medicine highlights lung cancer study results
By LabPulse.com staff writers
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
2021 11 10 18 26 8156 Science Genome Sequence Dna Map 400
Biodesix touts VeriStrat test results
By LabPulse.com staff writers
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Veracyte genomic test classifies lung cancer risk in study
By Dexter Johnson
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Veracyte's Percepta Genomic Sequencing Classifier (GSC) can accurately classify lung cancer risk from inconclusive samples taken in a bronchoscopy.
July 19, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Medial EarlySign, Roche partner on lung cancer detection
By LabPulse.com staff writers
The goal is to deliver validated clinical machine learning models for lung cancer detection with EarlySign's LungFlag technology. The technology uses a variety of signals, including basic demographic, medical, drug, and routine clinical lab data.
July 7, 2022
2022 01 25 22 49 5402 Lung 3 D 400
Philips adopting proteomics results for patient management
By LabPulse.com staff writers
The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.
June 29, 2022
2019 12 05 23 56 4761 Philips Rsna 2018 400
Foundation Medicine gets FDA nod for NSCLC CDx
By LabPulse.com staff writers
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400
Biodesix obtains Medicare coverage for lung nodule test
By LabPulse.com staff writers
According to Biodesix, Nodify CDT measures seven autoantibodies associated with tumor antigens to help providers detect lung cancer across all histologies and stages.
June 6, 2022
2020 04 30 21 13 0442 Medicare Puzzle 400
Previous Page
Page 2 of 7
Next Page